See more : Premier Miton Group plc (PASMF) Income Statement Analysis – Financial Results
Complete financial analysis of Hikma Pharmaceuticals PLC (HKMPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hikma Pharmaceuticals PLC, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Xenetic Biosciences, Inc. (XBIOW) Income Statement Analysis – Financial Results
- Baotou Tomorrow Technology Co., Ltd. (600091.SS) Income Statement Analysis – Financial Results
- TuHURA Biosciences, Inc. (HURA) Income Statement Analysis – Financial Results
- Town and Country Financial Corporation (TWCF) Income Statement Analysis – Financial Results
- Koszalinskie Przedsiebiorstwo Przemyslu Drzewnego Spólka Akcyjna (KPD.WA) Income Statement Analysis – Financial Results
Hikma Pharmaceuticals PLC (HKMPF)
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.88B | 2.52B | 2.55B | 2.34B | 2.21B | 2.07B | 1.94B | 1.95B | 1.44B | 1.49B | 1.37B | 1.11B | 918.03M | 730.94M | 636.88M | 580.66M | 448.80M | 317.02M | 262.22M | 212.38M | 105.15M | 85.50M |
| Cost of Revenue | 1.47B | 1.28B | 1.25B | 1.14B | 1.06B | 1.02B | 969.00M | 964.00M | 622.00M | 638.00M | 601.00M | 607.60M | 522.68M | 373.59M | 332.46M | 324.17M | 227.26M | 158.49M | 126.42M | 103.94M | 51.57M | 40.58M |
| Gross Profit | 1.41B | 1.24B | 1.30B | 1.20B | 1.15B | 1.05B | 967.00M | 986.00M | 818.00M | 851.00M | 764.00M | 501.12M | 395.35M | 357.34M | 304.43M | 256.48M | 221.53M | 158.53M | 135.79M | 108.44M | 53.58M | 44.92M |
| Gross Profit Ratio | 48.94% | 49.19% | 50.96% | 51.30% | 52.02% | 50.72% | 49.95% | 50.56% | 56.81% | 57.15% | 55.97% | 45.20% | 43.07% | 48.89% | 47.80% | 44.17% | 49.36% | 50.01% | 51.79% | 51.06% | 50.96% | 52.54% |
| Research & Development | 149.00M | 144.00M | 143.00M | 137.00M | 150.00M | 147.00M | 115.00M | 150.00M | 36.00M | 55.00M | 39.00M | 34.02M | 31.22M | 23.61M | 16.84M | 22.17M | 19.34M | 18.29M | 16.51M | 9.67M | 4.13M | 3.01M |
| General & Administrative | 638.00M | 509.00M | 488.00M | 464.00M | 453.00M | 246.00M | 238.00M | 208.00M | 180.00M | 185.00M | 151.00M | 124.56M | -43.12M | -29.85M | -38.86M | -47.35M | -17.67M | -4.96M | -4.76M | -4.63M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 494.00M | 224.00M | 188.00M | 184.00M | 156.00M | 171.00M | 160.00M | 152.76M | 125.30M | 106.67M | 98.08M | 90.56M | 61.02M | 35.01M | 27.37M | 19.73M | 0.00 | 0.00 |
| SG&A | 638.00M | 509.00M | 488.00M | 464.00M | 494.00M | 470.00M | 426.00M | 392.00M | 336.00M | 356.00M | 311.00M | 277.32M | 82.17M | 76.83M | 59.23M | 43.21M | 43.35M | 30.05M | 22.61M | 15.10M | 0.00 | 0.00 |
| Other Expenses | 253.00M | 0.00 | 0.00 | 0.00 | -50.88M | -59.22M | -60.92M | -88.83M | -54.02M | 0.00 | 0.00 | -1.17M | 2.33M | 0.00 | 0.00 | 0.00 | 0.00 | 938.00K | 1.45M | 732.00K | 0.00 | 0.00 |
| Operating Expenses | 1.04B | 756.00M | 742.00M | 687.00M | 655.00M | 690.00M | 635.00M | 611.00M | 401.00M | 449.00M | 412.00M | 334.34M | 276.73M | 222.04M | 197.80M | 176.64M | 129.34M | 84.16M | 67.59M | 46.06M | 22.62M | 20.29M |
| Cost & Expenses | 2.51B | 2.04B | 1.99B | 1.83B | 1.71B | 1.71B | 1.60B | 1.58B | 1.02B | 1.09B | 1.01B | 941.95M | 799.41M | 595.63M | 530.26M | 500.81M | 356.60M | 242.65M | 194.02M | 150.00M | 74.19M | 60.87M |
| Interest Income | 7.00M | 3.00M | 30.00M | 47.00M | 67.00M | 3.00M | 2.00M | 12.00M | 3.00M | 4.00M | 2.00M | 1.27M | 468.00K | 346.00K | 514.00K | 817.00K | 2.03M | 5.26M | 1.56M | 326.00K | 290.00K | 117.00K |
| Interest Expense | 90.00M | 77.00M | 69.00M | 69.00M | 67.00M | 80.00M | 60.00M | 104.00M | 57.00M | 38.00M | 37.00M | 35.72M | 23.37M | 13.86M | 12.83M | 17.55M | 10.84M | 4.96M | 5.21M | 3.83M | 1.90M | 2.55M |
| Depreciation & Amortization | 195.60M | 186.55M | 164.15M | 143.91M | 121.49M | 104.11M | 142.86M | 102.57M | 73.00M | 72.00M | 75.00M | 58.39M | 47.00M | 38.43M | 34.15M | 33.12M | 23.43M | 13.80M | 10.33M | 6.77M | 3.06M | 4.89M |
| EBITDA | 572.47M | 485.00M | 735.00M | 796.28M | 685.36M | 435.55M | -570.38M | 350.74M | 484.00M | 472.00M | 426.00M | 226.15M | 164.19M | 165.38M | 141.10M | 114.47M | 117.32M | 94.35M | 79.70M | 70.01M | 34.64M | 28.71M |
| EBITDA Ratio | 19.91% | 27.81% | 28.79% | 27.85% | 29.86% | 23.38% | 81.35% | 27.33% | 33.61% | 31.70% | 31.21% | 20.40% | 17.89% | 23.73% | 22.15% | 19.61% | 26.26% | 29.78% | 31.20% | 32.97% | 32.91% | 33.58% |
| Operating Income | 367.00M | 282.00M | 582.00M | 579.00M | 493.00M | 371.00M | -747.00M | 302.00M | 381.00M | 402.00M | 352.00M | 166.77M | 118.69M | 135.10M | 107.29M | 80.68M | 92.40M | 75.25M | 69.21M | 62.72M | 30.99M | 22.46M |
| Operating Income Ratio | 12.77% | 11.20% | 22.80% | 24.73% | 22.34% | 17.92% | -38.58% | 15.49% | 26.46% | 27.00% | 25.79% | 15.04% | 12.93% | 18.48% | 16.85% | 13.89% | 20.59% | 23.74% | 26.39% | 29.53% | 29.47% | 26.27% |
| Total Other Income/Expenses | -86.00M | -49.00M | -38.00M | -21.00M | -2.00M | -78.00M | 9.00M | -92.00M | -63.00M | -40.00M | -54.00M | -35.00M | -24.80M | -14.11M | -12.51M | -16.65M | -8.61M | 348.60K | -4.80M | -3.70M | -1.32M | -3.37M |
| Income Before Tax | 281.00M | 233.00M | 544.00M | 558.00M | 491.00M | 293.00M | -738.00M | 210.00M | 318.00M | 362.00M | 298.00M | 132.04M | 93.89M | 120.98M | 94.79M | 64.03M | 83.79M | 75.60M | 64.41M | 59.02M | 29.67M | 19.10M |
| Income Before Tax Ratio | 9.77% | 9.26% | 21.31% | 23.84% | 22.25% | 14.15% | -38.12% | 10.77% | 22.08% | 24.31% | 21.83% | 11.91% | 10.23% | 16.55% | 14.88% | 11.03% | 18.67% | 23.85% | 24.56% | 27.79% | 28.22% | 22.33% |
| Income Tax Expense | 89.00M | 42.00M | 124.00M | 128.00M | 4.00M | 8.00M | 101.00M | 52.00M | 64.00M | 80.00M | 82.00M | 24.83M | 10.42M | 21.46M | 15.47M | 6.92M | 19.60M | 19.64M | 19.45M | 20.84M | 11.91M | 8.52M |
| Net Income | 190.00M | 188.00M | 421.00M | 431.00M | 486.00M | 282.00M | -843.00M | 155.00M | 252.00M | 278.00M | 212.00M | 100.00M | 80.11M | 98.85M | 77.68M | 57.12M | 62.58M | 54.52M | 43.87M | 37.46M | 17.59M | 10.50M |
| Net Income Ratio | 6.61% | 7.47% | 16.49% | 18.41% | 22.02% | 13.62% | -43.54% | 7.95% | 17.50% | 18.67% | 15.53% | 9.02% | 8.73% | 13.52% | 12.20% | 9.84% | 13.94% | 17.20% | 16.73% | 17.64% | 16.73% | 12.28% |
| EPS | 0.86 | 0.82 | 1.79 | 1.95 | 2.09 | 1.17 | -3.51 | 0.67 | 1.27 | 1.40 | 1.08 | 0.51 | 0.41 | 0.51 | 0.41 | 0.30 | 0.37 | 0.33 | 0.30 | 26.30 | 0.11 | 0.06 |
| EPS Diluted | 0.85 | 0.82 | 1.78 | 1.93 | 2.08 | 1.17 | -3.50 | 0.66 | 1.25 | 1.39 | 1.07 | 0.51 | 0.41 | 0.50 | 0.40 | 0.30 | 0.35 | 0.31 | 0.28 | 24.80 | 0.11 | 0.06 |
| Weighted Avg Shares Out | 220.86M | 224.00M | 231.00M | 236.00M | 242.00M | 241.00M | 240.00M | 233.00M | 199.00M | 198.00M | 197.00M | 196.35M | 194.14M | 192.30M | 189.76M | 187.88M | 169.22M | 167.28M | 154.86M | 166.54M | 166.54M | 166.54M |
| Weighted Avg Shares Out (Dil) | 222.37M | 225.00M | 233.00M | 238.00M | 243.00M | 242.00M | 241.00M | 234.00M | 201.00M | 200.00M | 198.00M | 198.30M | 197.77M | 196.86M | 193.73M | 193.17M | 176.85M | 175.92M | 154.86M | 166.54M | 166.54M | 166.54M |
Hikma Pharmaceuticals to buy US generic sterile injectables producer Custopharm for US$375mln
Hikma Pharmaceuticals PLC announced it has agreed to acquire US-based generic sterile injectables producer Custopharm Inc. for US$375mln.
Hikma Pharmaceuticals' (HKMPF) CEO Sigurdur Olafsson on Q2 2021 Results - Earnings Call Transcript
Hikma Pharmaceuticals' (HKMPF) CEO Sigurdur Olafsson on Q2 2021 Results - Earnings Call Transcript
Hikma Pharmaceuticals first half revenue and profits grow
Hikma Pharmaceuticals Plc chief executive Siggi Olafsson said it benefited from the resilience in its portfolio and flexibility in manufacturing. The pharmaceutical company reported a 7% rise in revenue for the six months ended June 30, to US$1.21bn, whilst operating...
Here's Why "Trend" Investors Would Love Betting on Hikma Pharmaceuticals Plc (HKMPF)
Hikma Pharmaceuticals Plc (HKMPF) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Hikma Pharmaceuticals receives US approval for opioid overdose treatment Kloxxado
Hikma Pharmaceuticals PLC (LON:HIK) said the US Food and Drug Administration (FDA) has approved Kloxxado, its emergency treatment of known or suspected opioid overdose. It can be used on adult and paediatric patients and contains twice as much naloxone per...
Hikma Pharmaceuticals PLC (HKMPF) CEO Siggi Olafsson on Q4 2020 Results - Earnings Call Transcript
Hikma Pharmaceuticals PLC (HKMPF) CEO Siggi Olafsson on Q4 2020 Results - Earnings Call Transcript
Hikma Pharmaceuticals revenue growth expectations come in below consensus
Hikma Pharmaceuticals PLC (LON:HIK) said it expects revenue growth across all its segments in 2021, though it will be below consensus. Injectables and branded revenue is estimated to rise around 5%, while generics is expected to come in at US$770-810mln...
Hikma Pharmaceuticals revenue growth expectations come below consensus
Hikma Pharmaceuticals PLC (LON:HIK) said it expects revenue growth across all its segments in 2021, though it is coming below consensus. Injectables and branded revenue is estimated to rise around 5%, while generics is expected to come in at US$770-810mln...
Hikma Pharmaceuticals (OTCMKTS:HKMPF) Stock Rating Upgraded by Zacks Investment Research
Hikma Pharmaceuticals (OTCMKTS:HKMPF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday, Zacks.com reports. The brokerage currently has a $32.00 price objective on the stock. Zacks Investment Research‘s...
Source: https://incomestatements.info
Category: Stock Reports